SMTI vs. AVNS, ZJYL, INGN, LAKE, CLGN, NTRB, APT, MLSS, COCH, and RBOT
Should you be buying Sanara MedTech stock or one of its competitors? The main competitors of Sanara MedTech include Avanos Medical (AVNS), Jin Medical International (ZJYL), Inogen (INGN), Lakeland Industries (LAKE), CollPlant Biotechnologies (CLGN), Nutriband (NTRB), Alpha Pro Tech (APT), Milestone Scientific (MLSS), Envoy Medical (COCH), and Vicarious Surgical (RBOT). These companies are all part of the "surgical appliances & supplies" industry.
Avanos Medical (NYSE:AVNS) and Sanara MedTech (NASDAQ:SMTI) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, community ranking, institutional ownership, analyst recommendations, earnings, profitability, media sentiment and dividends.
Sanara MedTech has a consensus target price of $44.00, indicating a potential upside of 48.15%. Given Avanos Medical's stronger consensus rating and higher possible upside, analysts plainly believe Sanara MedTech is more favorable than Avanos Medical.
In the previous week, Avanos Medical had 7 more articles in the media than Sanara MedTech. MarketBeat recorded 8 mentions for Avanos Medical and 1 mentions for Sanara MedTech. Avanos Medical's average media sentiment score of 1.89 beat Sanara MedTech's score of -0.29 indicating that Sanara MedTech is being referred to more favorably in the news media.
95.2% of Avanos Medical shares are held by institutional investors. Comparatively, 8.1% of Sanara MedTech shares are held by institutional investors. 2.9% of Avanos Medical shares are held by company insiders. Comparatively, 54.1% of Sanara MedTech shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Sanara MedTech has lower revenue, but higher earnings than Avanos Medical. Sanara MedTech is trading at a lower price-to-earnings ratio than Avanos Medical, indicating that it is currently the more affordable of the two stocks.
Avanos Medical has a beta of 0.97, suggesting that its share price is 3% less volatile than the S&P 500. Comparatively, Sanara MedTech has a beta of 1.67, suggesting that its share price is 67% more volatile than the S&P 500.
Avanos Medical received 65 more outperform votes than Sanara MedTech when rated by MarketBeat users. Likewise, 54.97% of users gave Avanos Medical an outperform vote while only 54.55% of users gave Sanara MedTech an outperform vote.
Sanara MedTech has a net margin of -7.19% compared to Sanara MedTech's net margin of -9.15%. Sanara MedTech's return on equity of 4.10% beat Avanos Medical's return on equity.
Summary
Sanara MedTech beats Avanos Medical on 10 of the 18 factors compared between the two stocks.
Get Sanara MedTech News Delivered to You Automatically
Sign up to receive the latest news and ratings for SMTI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SMTI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Sanara MedTech Competitors List
Related Companies and Tools
